Log in

Relevant bibliographies by topics / End stage kidney disease / Journal articles

Journal articles on the topic 'End stage kidney disease'

To see the other types of publications on this topic, follow the link: End stage kidney disease.

Author: Grafiati

Published: 4 June 2021

Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'End stage kidney disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Crawford, Gregory B., Julie A. Robinson, Amy E. Z. Baker, and Susan M. Crail. "End-Stage Kidney Disease." American Journal of Hospice and Palliative Medicine® 31, no. 3 (April 11, 2013): 331–37. http://dx.doi.org/10.1177/1049909113484383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lanewala, AliAsghar. "Chronic kidney disease – End-stage kidney disease group." Asian Journal of Pediatric Nephrology 4, no. 1 (2021): 3. http://dx.doi.org/10.4103/ajpn.ajpn_24_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kuehn, Bridget M. "End-stage Kidney Disease Doubles." JAMA 327, no. 16 (April 26, 2022): 1540. http://dx.doi.org/10.1001/jama.2022.5342.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kuehn, Bridget M. "End-stage Kidney Disease Doubles." JAMA 327, no. 16 (April 26, 2022): 1540. http://dx.doi.org/10.1001/jama.2022.5342.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gupta, Ryan, Karen Woo, and Jeniann A. Yi. "Epidemiology of end-stage kidney disease." Seminars in Vascular Surgery 34, no. 1 (March 2021): 71–78. http://dx.doi.org/10.1053/j.semvascsurg.2021.02.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Farmakis, Christopher, and Roberto Collazo-Maldonado. "Hypertension in end-stage kidney disease." Hypertension Journal 7, no. 1 (2021): 14–18. http://dx.doi.org/10.15713/ins.johtn.0215.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Moss, Alvin H., Nancy Armistead, and Dale Lupu. "End-Stage Kidney Disease Without Dialysis." Health Affairs 34, no. 11 (November 2015): 2005. http://dx.doi.org/10.1377/hlthaff.2015.1225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wong, Jonathan, Enric Vilar, and Ken Farrington. "Endotoxemia in End-Stage Kidney Disease." Seminars in Dialysis 28, no. 1 (July 13, 2014): 59–67. http://dx.doi.org/10.1111/sdi.12280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hylek, Elaine M. "Apixaban for End-Stage Kidney Disease." Circulation 138, no. 15 (October 9, 2018): 1534–36. http://dx.doi.org/10.1161/circulationaha.118.036449.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Krishnan, Amrish, Yogeshni Chandra, Joji Malani, Shilpanjali Jesudason, Shaundeep Sen, and Angus G. Ritchie. "End‐stage kidney disease in Fiji." Internal Medicine Journal 49, no. 4 (April 2019): 461–66. http://dx.doi.org/10.1111/imj.14108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Willingham, Fiona. "Prehabilitation in end stage kidney disease." Journal of Kidney Care 8, Sup6 (November 1, 2023): S40—S46. http://dx.doi.org/10.12968/jokc.2023.8.sup6.s40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tsuruya, Kazuhiko, Masahiro Eriguchi, Shunsuke Yamada, Hideki Hirakata, and Takanari Kitazono. "Cardiorenal Syndrome in End-Stage Kidney Disease." Blood Purification 40, no. 4 (2015): 337–43. http://dx.doi.org/10.1159/000441583.

Full text

Abstract:

Background: Cardiorenal syndrome (CRS) in patients with end-stage kidney disease (ESKD) represents mainly cardiovascular disease (CVD) due to various complications associated with renal dysfunction—defined as type 4 CRS by Ronco et al.—because the effect of cardiac dysfunction on the kidneys does not need to be taken into consideration, unlike in non-dialysis dependent chronic kidney disease (CKD). Summary: Patients with ESKD are often in a state of chronic inflammation due to the upregulation of proinflammatory cytokines. Chronic inflammation leads to malnutrition and consequently to vascular endothelial dysfunction and vascular calcification, which is referred to as malnutrition-inflammation-atherosclerosis (MIA) syndrome and acts as a major risk factor for CVD. Anemia also plays a crucial role in CVD, and individuals with erythropoietin-resistant anemia have a particularly high risk of CVD. However, caution is emphasized because not only anemia itself, but also the overtreatment of anemia with erythropoiesis-stimulating agents aimed at elevating hemoglobin to ≥13 g/dl can also increase the risk of CVD. In CKD-mineral and bone disorder (CKD-MBD), phosphate load triggers the interactions between various factors such as calcium, parathyroid hormone, vitamin D, and fibroblast growth factor 23, promoting vascular calcification and thus becoming a risk factor for CVD. Key Messages: In addition to traditional atherosclerosis risk factors such as hypertension, diabetes, and dyslipidemia, the involvement of MIA syndrome, anemia, and CKD-MBD accompanying CKD have also become a focus for investigation as major players in CRS in patients with ESKD.

APA, Harvard, Vancouver, ISO, and other styles

13

Prabhu, RavindraAttur, Naveen Salins, Bharathi, and Georgi Abraham. "End of life care in end-stage kidney disease." Indian Journal of Palliative Care 27, no. 5 (2021): 37. http://dx.doi.org/10.4103/ijpc.ijpc_64_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Manian, Farrin A. "Medical Myths: Unprepared For The End Stages Of End-Stage Kidney Disease." Health Affairs 34, no. 9 (September 2015): 1599–602. http://dx.doi.org/10.1377/hlthaff.2014.0992.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Saraf, Santosh L., Jesse Y. Hsu, Ana C. Ricardo, Rupal Mehta, Jing Chen, Teresa K. Chen, Michael J. Fischer, et al. "Anemia and Incident End-Stage Kidney Disease." Kidney360 1, no. 7 (May 20, 2020): 623–30. http://dx.doi.org/10.34067/kid.0000852020.

Full text

Abstract:

BackgroundCKD progression can be a cause and potentially a consequence of anemia. Previous studies suggesting that anemia is associated with CKD progression have not used methodologic approaches to address time-dependent confounding.MethodsWe evaluated the association of anemia (defined using World Health Organization criteria of hemoglobin <12 g/dl in women and <13 g/dl in men) with incident ESKD and all-cause death in individuals with CKD using data from the Chronic Renal Insufficiency Cohort Study. Marginal structural models were used to account for time-dependent confounding.ResultsAmong 3919 participants, 1859 (47%) had anemia at baseline. Over median follow-up of 7.8 years, we observed 1010 ESKD events and 994 deaths. In multivariable analyses, individuals with anemia had higher risk for ESKD compared with those without (HR, 1.62; 95% CI, 1.24 to 2.11). In stratified analyses, the increased risk for incident ESKD with anemia was observed in males (HR, 2.15; 95% CI, 1.53 to 3.02) but not females (HR, 1.20; 95% CI, 0.82 to 1.78). The association between anemia and ESKD was significant among all racial/ethnic groups except non-Hispanic blacks (non-Hispanic white, HR, 2.16; 95% CI, 1.53 to 3.06; Hispanic, HR, 1.92; 95% CI, 1.04 to 3.51; others, HR, 2.94; 95% CI, 1.16 to 7.44; non-Hispanic black, HR, 1.39; 95% CI, 0.95 to 2.02). There was no association between anemia and all-cause death.ConclusionsIn this cohort, anemia was independently associated with increased risk for incident ESKD. Future work is needed to evaluate the mechanisms by which anemia leads to CKD progression as well as the effect of novel therapeutic agents to treat anemia.

APA, Harvard, Vancouver, ISO, and other styles

16

Koncicki, Holly M. "Characteristics of End-Stage Kidney Disease Patients." Nephrology Self-Assessment Program 20, no. 1 (August 2021): 49–61. http://dx.doi.org/10.1681/nsap.2021.20.1.4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Shirazian, Shayan, Piotr Starakiewicz, and Sheron Latcha. "Cancer Screening in End-Stage Kidney Disease." Advances in Chronic Kidney Disease 28, no. 5 (September 2021): 502–8. http://dx.doi.org/10.1053/j.ackd.2021.09.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Brown, James A. "End-Stage Autosomal Dominant Polycystic Kidney Disease." New England Journal of Medicine 347, no. 19 (November 7, 2002): 1504. http://dx.doi.org/10.1056/nejmicm020402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Manian, Farrin A. "End-Stage Kidney Disease: The Author Replies." Health Affairs 34, no. 11 (November 2015): 2005. http://dx.doi.org/10.1377/hlthaff.2015.1228.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Tanios, Bassem Y., Houssam S. Itani, and Deborah L. Zimmerman. "Clopidogrel Use in End-Stage Kidney Disease." Seminars in Dialysis 28, no. 3 (December 5, 2014): 276–81. http://dx.doi.org/10.1111/sdi.12338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Maroz, Natallia, and Mark S. Segal. "Lupus Nephritis and End-stage Kidney Disease." American Journal of the Medical Sciences 346, no. 4 (October 2013): 319–23. http://dx.doi.org/10.1097/maj.0b013e31827f4ee3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

FASSETT, ROBERT G., IAIN K. ROBERTSON, ROSE MACE, LOREN YOUL, SARAH CHALLENOR, and ROSALIND BULL. "Palliative care in end-stage kidney disease." Nephrology 16, no. 1 (December 23, 2010): 4–12. http://dx.doi.org/10.1111/j.1440-1797.2010.01409.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Boileau, Michel, Richard Foley, Stuart Flechner, and Edward Weinman. "Renal Adenocarcinoma and End Stage Kidney Disease." Journal of Urology 138, no. 3 (September 1987): 603–6. http://dx.doi.org/10.1016/s0022-5347(17)43271-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Wiederkehr, Michael. "Brown tumor complicating end-stage kidney disease." Clinical Nephrology – Case Studies 8, no. 01 (January 1, 2020): 72–79. http://dx.doi.org/10.5414/cncs110195.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Wong, Jonathan, Hassan Jeraj, Enric Vilar, Adie Viljoen, and Ken Farrington. "Endotoxin detection in end-stage kidney disease." Journal of Clinical Pathology 68, no. 1 (November 6, 2014): 73–78. http://dx.doi.org/10.1136/jclinpath-2014-202622.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Mir, Javaid Ahmad, Onaisa Aalia Mushtaq, and Bushra Mushtaq. "Clinical case report: Chronic kidney disease and ESKD (End stage kidney disease)." IP Journal of Paediatrics and Nursing Science 5, no. 3 (September 15, 2022): 145–54. http://dx.doi.org/10.18231/j.ijpns.2022.024.

Full text

Abstract:

Chronic kidney disease include fibrosis, loss of renal cells and infiltration of renal tissue by monocytes and macrophages. The pathophysiology may include protein uria, hypoxia and excessive angiotensive II production. Hypoxia also contributes to disease progression. The disease has a vast number of clinical manifestations which include abnormalities in laboratory tests, hypertension, fatigue and poor appetite. There are five stages of CKD and in stage 5 the full blown clinical manifestations of end -stage renal disease are evident.Medical this disease can be managed by:1. Controlling blood pressure. 2. Managing blood glucose level to maintain HbA1c below 7%. 3. Managing hyperlipidemia with diet and cholesterol lowering drugs. 3. Managing and treating emerging manifestations of renal failure. 4. Prepare clients for renal replacement therapy when necessary. Patients condition (general condition) was fair, GCS 15/15,but had ineffective coping strategies, he was very much worried about his condition & renal transplant. He was not satisfied about the treatment received. Doctors have planned to discharge him till they arrange a donor for kidney.

APA, Harvard, Vancouver, ISO, and other styles

27

Singh, Jagmeet, Sushmita Khadka, Dhanshree Solanki, Asim Kichloo, Harshil Shah, Manasee J. Vyas, Savneek Chugh, Neil Patel, and Shantanu Solanki. "Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States." SAGE Open Medicine 9 (January 2021): 205031212110229. http://dx.doi.org/10.1177/20503121211022996.

Full text

Abstract:

Background: It is well-known that patients with chronic kidney disease and end-stage renal disease are at increased risk of pulmonary embolism than patients with normal kidney function. However, the data on trends, outcomes, and predictors of mortality in pulmonary embolism patients with chronic kidney disease and end-stage renal disease in the United States are limited. Methods: We queried the National Inpatient Sample database from 2010 to 2014. International Classification of Diseases-Ninth Revision-Clinical Modification codes were used to identify patients with normal kidney function, chronic kidney disease, and end-stage renal disease. The frequency of pulmonary embolism, complications, in-hospital mortality, and length of stay were calculated for each cohort. Multivariable logistic regression models were constructed to determine the predictors of mortality. Results: In the study population (2010–2014), there were 766,176 pulmonary embolism hospitalizations with normal kidney function, 79,824 with chronic kidney disease, and 9147 with end-stage renal disease. Among the study cohorts, the mortality rate was 2.7% in normal kidney function, 4.5% in chronic kidney disease, and 6.8% in end-stage renal disease hospitalizations. Median length of stay was highest in the end-stage renal disease cohort and lowest in the normal kidney function cohort. After adjusting for confounders, pulmonary embolism patients with chronic kidney disease died 1.15 times more often than those with normal kidney function and pulmonary embolism patients with end-stage renal disease died 4.2 times more often than those with normal kidney function. Conclusion: The mortality rate and length of stay in pulmonary embolism patients with chronic kidney disease and end-stage renal disease were significantly higher than those in pulmonary embolism patients with normal kidney function. Also, pulmonary embolism patients with chronic kidney disease and end-stage renal disease were at higher risk of in-hospital mortality than those with normal kidney function. There was statistically significant higher risk of mortality in elderly and Black patients with pulmonary embolism and concurrent chronic kidney disease or end-stage renal disease.

APA, Harvard, Vancouver, ISO, and other styles

28

Yang, Chih-Wei, David C. H. Harris, Valerie A. Luyckx, Masaomi Nangaku, Fan Fan Hou, Guillermo Garcia Garcia, Hasan Abu-Aisha, et al. "Global case studies for chronic kidney disease/end-stage kidney disease care." Kidney International Supplements 10, no. 1 (March 2020): e24-e48. http://dx.doi.org/10.1016/j.kisu.2019.11.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ellis, Robert J., Daniel P. Edey, Sharon J. Del Vecchio, Megan McStea, Scott B. Campbell, Carmel M. Hawley, David W. Johnson, et al. "End-Stage Kidney Disease following Surgical Management of Kidney Cancer." Clinical Journal of the American Society of Nephrology 13, no. 11 (September 28, 2018): 1641–48. http://dx.doi.org/10.2215/cjn.06560518.

Full text

Abstract:

Background and objectivesWe investigated the incidence of ESKD after surgical management of kidney cancer in the Australian state of Queensland, and described patterns in the initiation of kidney replacement therapy resulting from kidney cancer across Australia.Design, setting, participants, & measurementsAll newly diagnosed cases of kidney cancer in the Australian state of Queensland between January of 2009 and December of 2014 were ascertained through the Queensland Cancer Registry. There were 2739 patients included in our analysis. Patients who developed ESKD were identified using international classification of disease–10–coded hospital administrative data. Incidence rate and 3-year cumulative incidence were calculated, and multivariable Cox proportional hazards models were used to identify factors associated with ESKD. Additional descriptive analysis was undertaken of Australian population data.ResultsThe incidence rate of ESKD in all patients was 4.9 (95% confidence interval [95% CI], 3.9 to 6.2) per 1000 patient-years. The 3-year cumulative incidence was 1.7%, 1.9%, and 1.0% for all patients, and patients managed with radical or partial nephrectomy, respectively. Apart from preoperative kidney disease, exposures associated with increased ESKD risk were age≥65 years (adjusted hazard ratio [aHR], 2.0; 95% CI, 1.2 to 3.2), male sex (aHR, 2.3; 95% CI, 1.3 to 4.3), preoperative diabetes (aHR, 1.8; 95% CI, 1.0 to 3.3), American Society of Anesthesiologists classification ≥3 (aHR, 4.0; 95% CI, 2.2 to 7.4), socioeconomic disadvantage (aHR, 1.6; 95% CI, 0.9 to 2.7), and postoperative length of hospitalization ≥6 days (aHR, 2.1; 95% CI, 1.4 to 3.0). Australia-wide trends indicate that the rate of kidney replacement therapy after oncologic nephrectomy doubled between 1995 and 2015, from 0.3 to 0.6 per 100,000 per year.ConclusionsIn Queensland between 2009 and 2014, one in 53 patients managed with radical nephrectomy and one in 100 patients managed with partial nephrectomy developed ESKD within 3 years of surgery.PodcastThis article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_09_28_CJASNPodcast_18_1_.mp3

APA, Harvard, Vancouver, ISO, and other styles

30

Żuberek, Michał, Zuzanna Popińska, Daniel Ślusarczyk, Bartłomiej Żmuda, Wiktoria Jakubowska, Piotr Pisera, Aleksandra Kiełkowicz, and Filip Pactwa. "A review on the classification and current treatment of Chronic Kidney Disease." Journal of Education, Health and Sport 49, no. 1 (December 28, 2023): 86–106. http://dx.doi.org/10.12775/jehs.2023.49.01.006.

Full text

Abstract:

Introduction: Chronic Kidney Disease (CKD) is a chronic condition which is characterized by the gradual loss of kidney function over time leading to End-Stage Renal Disease (ESRD). Role of kidneys is very vital to maintain homeostasis of the system. CKD is classified into five stages based on the estimated Glomerular Filtration Rate (eGFR). CKD is a long-term condition which cannot be completely cured. Treatment focuses on managing underlying conditions , slowing disease progression and addressing complications. Aim of the study: Purpose of this study is to encapsulate available knowledge about classification and therapeutic options for patients with Chronic Kidney Disease and End-Stage Kidney Disease. Both old and new treatment methods have been summarized in the following publication. Material and methods: Literature available in the PubMed database was reviewed using the following keywords: “Chronic kidney disease”, “ACE inhibitors” , “Angiotensin II Type 1 Receptor Blockers", “Diabetic Kidney Disease” ,”End-Stage Kidney Disease”, “Dapagliflozin”, Conclusions: Chronic Kidney Disease is a condition which is progressive and affects more than 10% of the general population worldwide totaling over 800 million people. There are many causes of chronic kidney disease; therefore, it is important to focus on slowing the progression of the disease, minimizing complications and modifying risk factors.

APA, Harvard, Vancouver, ISO, and other styles

31

Hanif, Muhammad, Hina Javed, Umair Jallani, and Nazar Muhammad Ranjha. "Prevalence of end stage renal disease in diabetic obese and hypertensive patients and cardiovascular risk in dialysis patients." Pakistan Journal of Pharmaceutical Research 2, no. 1 (January 27, 2016): 42. http://dx.doi.org/10.22200/pjpr.2016142-48.

Full text

Abstract:

Chronic kidney disease(CKD) is the cause of irreversible detoriation of renal function which leads to end stage renal disease(ESRD).incidence of end stage renal disease has increased dramatically during last 30 years and screening for early stages of chronic kidney disease is often suggested as preventive measure.the main cause of end stage renal disease are diabetes, high blood pressure,hyperlipidemia and obesity.obesity and increased BMI are the cause of kidney stone and chronic kidney disease.this reports aim to determine the prevalance of end stage renal disease in diabetic obese individuals and other problems that are more likely to be encountered in the end stage renal disease are cardiovascular risks in dialysis patients.GFR and creatinine clearance are used as the major diagnostic tool to determined the kidney function. calcium level is also used as predictive factor to determine the vascular calcification.

APA, Harvard, Vancouver, ISO, and other styles

32

Nalesso, Federico, Francesco Garzotto, Leda Cattarin, Elisabetta Bettin, Martina Cacciapuoti, Cristina Silvestre, Lucia F. Stefanelli, Lucrezia Furian, and Lorenzo A. Calò. "The Future for End-Stage Kidney Disease Treatment: Implantable Bioartificial Kidney Challenge." Applied Sciences 14, no. 2 (January 5, 2024): 491. http://dx.doi.org/10.3390/app14020491.

Full text

Abstract:

Despite limited organ availability and post-transplant complications, kidney transplantation remains the optimal treatment for End-Stage Kidney Disease (ESKD). However, innovative dialysis technologies such as portable, wearable, and implantable bioartificial kidney systems are being developed with the aim of addressing these issues and improving patient care. An ideal implantable device could combine bioreactors and blood ultrafiltration to replicate key native cell functions for solute reabsorption, secretion, and endocrinologic activities. Today, the feasibility of an implantable bioreactor for renal cell therapy opens the challenge of developing a fully implantable bioartificial kidney based on silicon nanopore membranes to ensure immunological isolation, cell viability, and the possibility of maintaining a blood substrate for metabolic activities. Current technology is not sufficient to obtain an efficient artificial bioreactor to reach physiological blood purification, which requires a more complex system to produce an ultrafiltrate from the blood that can be processed by cells and eliminated as urine. The number of cells in the bioreactor, endocrine activity, immunological cell isolation, solute and fluid secretion/reabsorption, cell viability, blood and ultrafiltration flow control, and thrombogenicity are fundamental issues that require a new technology that today appears to be a challenge for the design of an implantable artificial kidney. This review aims to analyze the state of the art in this particular field of kidney replacement therapy to highlight the current limitations and possible future technology developments to create implanted and wearable organs capable of treating ESKD with artificial organs that can replicate all native kidneys functions.

APA, Harvard, Vancouver, ISO, and other styles

33

Palat, Gayatri, Srinivas Vinayak Shenoy, Lakshmitha Shetty, and Sivakumar Vishnubhotla. "Comprehensive Conservative Care in End-Stage Kidney Disease." Indian Journal of Palliative Care 27 (May 30, 2021): S11—S13. http://dx.doi.org/10.4103/ijpc.ijpc_63_21.

Full text

Abstract:

In patients with end-stage kidney disease (ESKD), when there maybe situations where dialysis does not offer benefits in terms of survival or health-related quality of life, dialysis should not be viewed as the default therapy. Such patients can be offered comprehensive conservative care as an alternative to dialysis. Conservative (nondialytic) management of ESKD includes careful attention to fluid balance, treatment of anemia, correction of acidosis and hyperkalemia, blood pressure, and calcium/phosphorus metabolism management and dietary modification. Individualized symptom management and supportive care are crucial to maximize the quality of life. We propose that model of comprehensive conservative care in ESKD should manage both diseases as well as provide supportive care. Facilitating implementation of comprehensive conservative care requires coordination between nephrology and palliative care at patient, professional, administrative, and social levels to maximize benefit with the motto to improve the overall quality of life.

APA, Harvard, Vancouver, ISO, and other styles

34

So, Sarah, Frank P. Brennan, Kelly Chenlei Li, and Mark A. Brown. "End-stage kidney disease: The last 12 months." Australian Journal of General Practice 50, no. 4 (April 1, 2021): 193–98. http://dx.doi.org/10.31128/ajgp-11-20-5736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Rodrigues Chuva, Maria Teresa, José Maximino Costa, Joselina Barbosa, Sandra Silva, Paulo Santos, and Alfredo Loureiro. "SP705CANCER AND END-STAGE KIDNEY DISEASE: DEATH SENTENCE?" Nephrology Dialysis Transplantation 30, suppl_3 (May 2015): iii611—iii612. http://dx.doi.org/10.1093/ndt/gfv200.24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Janus, Nicolas, and Vincent Launay-Vacher. "Anticancer Drugs in End-Stage Kidney Disease Patients." Seminars in Dialysis 28, no. 4 (April 11, 2015): 413–16. http://dx.doi.org/10.1111/sdi.12371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Lew, Susie Q., and Ashté Collins. "When end‐stage kidney disease complicates abdominal surgery." Seminars in Dialysis 33, no. 3 (April 10, 2020): 270–78. http://dx.doi.org/10.1111/sdi.12872.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Vivante, Asaf, Ronit Calderon-Margalit, and Karl Skorecki. "Hematuria and risk for end-stage kidney disease." Current Opinion in Nephrology and Hypertension 22, no. 3 (May 2013): 325–30. http://dx.doi.org/10.1097/mnh.0b013e32835f7241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Oliverio, Andrea L., and Michelle A. Hladunewich. "End-Stage Kidney Disease and Dialysis in Pregnancy." Advances in Chronic Kidney Disease 27, no. 6 (November 2020): 477–85. http://dx.doi.org/10.1053/j.ackd.2020.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Park, Jongha, Seyed-Foad Ahmadi, Elani Streja, Miklos Z. Molnar, Katherine M. Flegal, Daniel Gillen, Csaba P. Kovesdy, and Kamyar Kalantar-Zadeh. "Obesity Paradox in End-Stage Kidney Disease Patients." Progress in Cardiovascular Diseases 56, no. 4 (January 2014): 415–25. http://dx.doi.org/10.1016/j.pcad.2013.10.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bates, Jane, Alex Chitani, and Gavin Dreyer. "Caring for patients with end-stage kidney disease." Lancet 386, no. 9996 (August 2015): 854–55. http://dx.doi.org/10.1016/s0140-6736(15)00013-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Gehrig, J. J., T. I. Gottheiner, and R. S. Swenson. "Acquired Cystic Disease of the End-Stage Kidney." Journal of Urology 135, no. 4 (April 1986): 885. http://dx.doi.org/10.1016/s0022-5347(17)45902-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Fehrman-Ekholm, I., G. Nordén, A. Lennerling, M. Rizell, H. Herlitz, F. D. Nielsen, O. Storkamp, S. I. Deurell, and M. Olausson. "Living Kidney Donors Developing End-Stage Renal Disease." Transplantation Proceedings 38, no. 8 (October 2006): 2642–43. http://dx.doi.org/10.1016/j.transproceed.2006.07.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Gehrig, James J., Toby I. Gottheiner, and Robert S. Swenson. "Acquired cystic disease of the end-stage kidney." American Journal of Medicine 79, no. 5 (November 1985): 609–20. http://dx.doi.org/10.1016/0002-9343(85)90059-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Boudville, Neil, and Amit X. Garg. "End-stage renal disease in living kidney donors." Kidney International 86, no. 1 (July 2014): 20–22. http://dx.doi.org/10.1038/ki.2013.560.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Barsoum, Rashad S. "Burden of end-stage kidney disease: North Africa." Clinical Nephrology 86, S1 (December 1, 2016): 14–17. http://dx.doi.org/10.5414/cnp86s102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

De La Mata, Nicole L., Philip Masson, Rustam Al-Shahi Salman, Patrick J. Kelly, and Angela C. Webster. "Death From Stroke in End-Stage Kidney Disease." Stroke 50, no. 2 (February 2019): 487–90. http://dx.doi.org/10.1161/strokeaha.118.023644.

Full text

Abstract:

Background and Purpose— People with end-stage kidney disease (ESKD) are at greater risk of stroke. We aimed to compare stroke mortality between the ESKD population and the general population. Methods— We included all patients with incident ESKD in Australia, 1980 to 2013, and New Zealand, 1988 to 2012. The primary cause of death was ascertained using data linkage with national death registers. We produced standardized mortality ratios for stroke deaths, by age, sex, and calendar year. Results— We included 60 823 patients with ESKD, where 941 stroke deaths occurred during 381 874 person-years. Patients with ESKD had >3× the stroke deaths compared with the general population (standardized mortality ratio, 3.4; 95% CI, 3.2–3.6), markedly higher in younger people and women. The greatest excess was in intracerebral hemorrhages (standardized mortality ratio, 5.2; 95% CI, 4.5–5.9). Excess stroke deaths in patients with ESKD decreased over time, although were still double in 2013 (2013 standardized mortality ratio, 2.1; 95% CI, 1.5–2.9). Conclusions— People with ESKD experience much greater stroke mortality with the greatest difference for women and younger people. However, mortality has improved over time.

APA, Harvard, Vancouver, ISO, and other styles

48

Ho-Hsieh, Hwei, Andrew C. Novick, Donald Steinmuller, Stevan B. Streem, Caroline Buszta, and Marlene Goormastic. "Renal transplantation for end-stage polycystic kidney disease." Urology 30, no. 4 (October 1987): 322–26. http://dx.doi.org/10.1016/0090-4295(87)90293-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Koncicki, Holly M. "Characteristics of Patients with End-Stage Kidney Disease." Nephrology Self-Assessment Program 22, no. 2 (August 2023): 140–50. http://dx.doi.org/10.58483/nsap.00392022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lynch, Matthew R., and Susie L. Hu. "Onco-nephrology highlights: Chronic kidney disease, end-stage kidney disease, and cancer patients." Journal of Onco-Nephrology 4, no. 1-2 (February 2020): 7–14. http://dx.doi.org/10.1177/2399369320918256.

Full text

Abstract:

With increasing prevalence of both kidney disease and cancer, patients who have both are common. Toxicity from treatment or direct kidney injury by the cancer itself can lead to acute kidney injury or progression of pre-existing chronic kidney disease. Management of advanced chronic kidney disease or end-stage kidney disease among those with concomitant cancer is challenging; however, better understanding of complications in this population will allow for optimization of treatments. Strategies for medication dosing, judicious use of erythropoiesis-stimulating agents in anemia, and treatment options for mineral bone disorders will be reviewed. Among those who require dialysis, special consideration should be made surrounding medication dosing, and end-of-life care should be addressed as early as possible in a patient-centered manner.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!